- https://www.origenis.de
- Business segment: Drug Discovery, Product Developer
- Origenis GmbH
- Am Klopferspitz 19 A
- 82152 Planegg/Martinsried
- Germany
- Phone: +49 (0)89/78 01 67 60
- Fax: +49 (0)89/78 01 67 67 77
- ed.sinegiro@ofni
Origenis
Dr. Andreas Treml, Geschäftsführer / Managing Director;
Dr. Michael Thormann, Geschäftsführer / Managing Director;
Michael Almstetter, Geschäftsführer / Managing Director
About Origenis
Origenis was founded in October 2005 through a management buy-out by Michael Almstetter, Dr. Michael Thormann, and Dr. Andreas Treml, who decided to continue the development and application of their technology platform and research programs together with the drug discovery team they had built up. We moved our labs and offices into IZB in 2006 because it represented a great chance to build up something new, to turn novel scientific ideas into new technologies and finally into sustainable industrial success by fueling drug development pipelines and delivering clinical candidates. Our computer-driven design and optimization drug discovery engine MolMind® /MOREsystem® was beyond revolutionary in 2005, and we have kept expanding it with Cippix® and evolving it into the most advanced small molecule AI innovation platform. Origenis has grown organically from nine team members in 2005 to about thirty in 2020, who work together as a cross- unctional, interdisciplinary, integrated, international team.
What is your motivation?
Origenis’ vision is to cure diseases with novel small molecule drugs where no drugs have been discovered yet. Therefore, we build and apply our AI innovation platform to create the drugs of the future. Our synergistic small molecule drug pipelines are either target-centric or disease-centric, or organ- entric: we pursue for example highly selective protein kinase inhibitors or protease inhibitors in difficult-to-reach tissues. Our BRAINstorm™ and EYEdeal™ technologies provide the key data to overcome the blood-brain- arrier and tear film that prevents most other drugs from reaching their target organ. Our team of highly skilled scientists uses stateof- the-art technologies in silico and in the wet lab to ensure a seamless transition from design to synthesis and characterization of novel compounds, while data feedback improves our AI, makes it faster, more precise and improves its success rate and decision making.
“wl*Labs + wn*Network + wo*Offices + ws*Site = Success.”
Dr. Andreas Treml, Geschäftsführer / Managing Director;
Dr. Michael Thormann, Geschäftsführer / Managing Director;
Michael Almstetter, Geschäftsführer / Managing Director
